Biogen (BIIB.O) weighed down the S&P 500, falling 4.7 percent to $278.96 after two brokerages downgraded the stock. "Healthcare is being …
healthcare stocks
U.S. biotech's shares slip 2.2 pct to $286.92 premarket on Morgan Stanley and Leerink downgrades ** Morgan Stanley downgrades to "equal weight" from "overweight", cuts PT to $305 from $369 ** "This is not a downside …
Morgan Stanley
Research Report for: Biogen Inc. (NASDAQ:BIIB) The highest price BIIB
para duelo
Biogen Inc (NASDAQ:BIIB) stock is getting whacked in sympathy to Eli Lilly and Co (NYSE:LLY)‘s announcement that it has once again failed in its quest to prove solanezumab to be a viable treatment for …
Eli Lilly and Company
Biogen (NASDAQ: BIIB) weighed down the Nasdaq, after two brokerages downgraded the stock, while AbbVie (NYSE: ABBV) was the biggest …
budget plan
Morgan Stanley downgraded its rating on shares of Biogen Inc. (BIIB) Thursday morning to "Equal weight" from "Overweight." Biogen gapped open sharply lower Thursday and steadily declined until mid-morning. The stock
Biogen Inc
Below is a chart showing MPC's trailing twelve month trading history, with the $50 strike highlighted in orange: Today's Most Active Call & Put Options of the S&P 500 » Biogen Inc (BIIB) options are showing a volume of …
underlying shares
Biogen Hit by Analyst Downgrades Biogen, known for its presence in the multiple sclerosis (MS) market, suffered a blow with a couple of …
Biotech Stocks
Investors in Biogen Idec Inc (NASD: BIIB) saw new options begin trading today, for the September 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new …